S&P 500   3,266.36 (+0.61%)
DOW   26,913.38 (+0.37%)
QQQ   267.95 (+0.96%)
AAPL   110.17 (+1.80%)
MSFT   206.05 (+1.41%)
FB   250.29 (+0.30%)
GOOGL   1,424.10 (+0.09%)
AMZN   3,040.11 (+0.67%)
TSLA   402.17 (+3.71%)
NVDA   504.79 (+2.20%)
BABA   267.78 (-0.72%)
CGC   13.92 (-2.45%)
GE   6.04 (-0.33%)
MU   48.31 (-2.34%)
AMD   76.59 (+1.02%)
T   27.83 (-0.75%)
F   6.53 (-1.95%)
ACB   4.99 (-4.04%)
GILD   61.91 (-0.55%)
NFLX   476.35 (+0.69%)
DIS   122.45 (-0.03%)
BAC   23.28 (-0.26%)
BA   150.58 (+3.10%)
S&P 500   3,266.36 (+0.61%)
DOW   26,913.38 (+0.37%)
QQQ   267.95 (+0.96%)
AAPL   110.17 (+1.80%)
MSFT   206.05 (+1.41%)
FB   250.29 (+0.30%)
GOOGL   1,424.10 (+0.09%)
AMZN   3,040.11 (+0.67%)
TSLA   402.17 (+3.71%)
NVDA   504.79 (+2.20%)
BABA   267.78 (-0.72%)
CGC   13.92 (-2.45%)
GE   6.04 (-0.33%)
MU   48.31 (-2.34%)
AMD   76.59 (+1.02%)
T   27.83 (-0.75%)
F   6.53 (-1.95%)
ACB   4.99 (-4.04%)
GILD   61.91 (-0.55%)
NFLX   476.35 (+0.69%)
DIS   122.45 (-0.03%)
BAC   23.28 (-0.26%)
BA   150.58 (+3.10%)
S&P 500   3,266.36 (+0.61%)
DOW   26,913.38 (+0.37%)
QQQ   267.95 (+0.96%)
AAPL   110.17 (+1.80%)
MSFT   206.05 (+1.41%)
FB   250.29 (+0.30%)
GOOGL   1,424.10 (+0.09%)
AMZN   3,040.11 (+0.67%)
TSLA   402.17 (+3.71%)
NVDA   504.79 (+2.20%)
BABA   267.78 (-0.72%)
CGC   13.92 (-2.45%)
GE   6.04 (-0.33%)
MU   48.31 (-2.34%)
AMD   76.59 (+1.02%)
T   27.83 (-0.75%)
F   6.53 (-1.95%)
ACB   4.99 (-4.04%)
GILD   61.91 (-0.55%)
NFLX   476.35 (+0.69%)
DIS   122.45 (-0.03%)
BAC   23.28 (-0.26%)
BA   150.58 (+3.10%)
S&P 500   3,266.36 (+0.61%)
DOW   26,913.38 (+0.37%)
QQQ   267.95 (+0.96%)
AAPL   110.17 (+1.80%)
MSFT   206.05 (+1.41%)
FB   250.29 (+0.30%)
GOOGL   1,424.10 (+0.09%)
AMZN   3,040.11 (+0.67%)
TSLA   402.17 (+3.71%)
NVDA   504.79 (+2.20%)
BABA   267.78 (-0.72%)
CGC   13.92 (-2.45%)
GE   6.04 (-0.33%)
MU   48.31 (-2.34%)
AMD   76.59 (+1.02%)
T   27.83 (-0.75%)
F   6.53 (-1.95%)
ACB   4.99 (-4.04%)
GILD   61.91 (-0.55%)
NFLX   476.35 (+0.69%)
DIS   122.45 (-0.03%)
BAC   23.28 (-0.26%)
BA   150.58 (+3.10%)
Log in
NASDAQ:NRIX

Nurix Therapeutics Stock Forecast, Price & News

$29.40
+0.99 (+3.48 %)
(As of 09/25/2020 12:22 PM ET)
Add
Compare
Today's Range
$28.72
Now: $29.40
$29.50
50-Day Range N/A
52-Week Range
$15.21
Now: $29.40
$37.46
Volume1,676 shs
Average Volume263,447 shs
Market Capitalization$1.09 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications. It also provides DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a class of enzymes that could modulate proteins within the cell. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc.; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was founded in 2009 and is headquartered in San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.63 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NRIX
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees103
Market Cap$1.09 billion
Next Earnings DateN/A
OptionableNot Optionable
$29.40
+0.99 (+3.48 %)
(As of 09/25/2020 12:22 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NRIX News and Ratings via Email

Sign-up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Nurix Therapeutics (NASDAQ:NRIX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Nurix Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nurix Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Nurix Therapeutics
.

What price target have analysts set for NRIX?

4 Wall Street analysts have issued 1 year target prices for Nurix Therapeutics' stock. Their forecasts range from $34.00 to $40.00. On average, they expect Nurix Therapeutics' share price to reach $36.00 in the next twelve months. This suggests a possible upside of 22.4% from the stock's current price.
View analysts' price targets for Nurix Therapeutics
.

Who are some of Nurix Therapeutics' key competitors?

What other stocks do shareholders of Nurix Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nurix Therapeutics investors own include AbbVie (ABBV), Datadog (DDOG), Docusign (DOCU), Fastly (FSLY), JPMorgan Chase & Co. (JPM), Lovesac (LOVE), NIO (NIO), Overstock.com (OSTK), Pinduoduo (PDD) and Shopify (SHOP).

Who are Nurix Therapeutics' key executives?

Nurix Therapeutics' management team includes the following people:
  • Dr. Arthur T. Sands, CEO, Pres & Director (Age 58, Pay $1.13M)
  • Dr. Gwenn Hansen Ph.D., Chief Scientific Officer (Age 49, Pay $601.55k)
  • Dr. Pierre Beaurang, Chief Bus. Officer (Age 50, Pay $597.67k)
  • Dr. John Kuriyan, Founder
  • Dr. Michael Rapé Ph.D., Founder

When did Nurix Therapeutics IPO?

(NRIX) raised $150 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel served as the underwriters for the IPO and Needham & Company was co-manager.

What is Nurix Therapeutics' stock symbol?

Nurix Therapeutics trades on the NASDAQ under the ticker symbol "NRIX."

When did Nurix Therapeutics' quiet period expire?

Nurix Therapeutics' quiet period expired on Wednesday, September 2nd. Nurix Therapeutics had issued 11,000,000 shares in its public offering on July 24th. The total size of the offering was $209,000,000 based on an initial share price of $19.00. During Nurix Therapeutics' quiet period, insiders and underwriters that worked on the IPO were prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Nurix Therapeutics?

Shares of NRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nurix Therapeutics' stock price today?

One share of NRIX stock can currently be purchased for approximately $29.40.

How big of a company is Nurix Therapeutics?

Nurix Therapeutics has a market capitalization of $1.09 billion. Nurix Therapeutics employs 103 workers across the globe.

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.